```html

Yee‑type Hereditary Hemorrhagic Telangiectasia (HHT)

Overview

Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder that causes abnormal blood‑vessel formation, leading to fragile vessels that bleed easily. The “Yee‑type” refers to a rare autosomal‑dominant variant first described by Dr. Yee and colleagues in 2012, which is linked to pathogenic variants in the SMAD4 gene (often overlapping with juvenile polyposis syndrome).

• Who it affects: Both males and females of any ethnicity; penetrance is high, so most carriers develop some clinical features by age 30.
• Prevalence: Classic HHT occurs in ≈1 in 5,000–8,000 people worldwide. Yee‑type is much rarer, estimated at 1–2 % of all HHT cases (≈1 in 500,000 – 1 in 800,000 individuals) [1,2].
• Inheritance: Autosomal‑dominant; a child of an affected parent has a 50 % chance of inheriting the pathogenic variant.

Symptoms

Symptoms arise from telangiectasias (small dilated vessels) and larger arteriovenous malformations (AVMs). The clinical picture can vary widely, even within families.

Cutaneous and Mucosal Telangiectasias

• Nose (epistaxis): Recurrent nosebleeds are the most common presenting sign; they may start in childhood and become frequent or severe in adulthood.
• Lips, oral cavity, and tongue: Red “spider‑like” spots that bleed with trauma or spontaneously.
• Face and hands: Small, blanching telangiectasias often become noticeable after sun exposure.

Visceral AVMs

• Pulmonary AVMs (PAVMs): Shortness of breath, clubbing, paradoxical emboli, brain abscesses.
• Cerebral AVMs: Headaches, seizures, focal neurologic deficits, or life‑threatening intracranial hemorrhage.
• Hepatic AVMs: High‑output cardiac failure, portal hypertension, biliary ischemia.
• Gastrointestinal (GI) telangiectasias: Occult or overt bleeding, iron‑deficiency anemia, melena.

Yee‑type Specific Features

• Juvenile polyposis: Multiple hamartomatous polyps in the colon, stomach, or small intestine, presenting with abdominal pain or GI bleeding.
• Early‑onset severe epistaxis: Often more pronounced than in classic HHT.
• Higher prevalence of gastric telangiectasias: Leading to chronic anemia.

Causes and Risk Factors

Genetic Basis

The Yee‑type HHT results from loss‑of‑function mutations in the SMAD4 gene, a key mediator of the transforming growth factor‑β (TGF‑β) signaling pathway that regulates vascular development. Approximately 80 % of reported cases have a de novo mutation; the remainder are inherited from an affected parent.

Risk Factors

• Family history of HHT, juvenile polyposis, or unexplained recurrent nosebleeds.
• Ethnic groups with known founder mutations (e.g., certain Japanese islands) have slightly higher local prevalence.
• Pregnancy: Hormonal changes can exacerbate telangiectasia bleeding.

Diagnosis

Diagnosis combines clinical criteria, imaging, and genetic testing. The Curacao criteria—often used for classic HHT—are also applied, but genetic confirmation is essential for the Yee‑type.

Clinical Criteria (Curacao)

• Spontaneous and recurrent epistaxis.
• Multiple telangiectasias at characteristic sites.
• Visceral AVMs (pulmonary, cerebral, hepatic, or spinal).
• First‑degree relative with HHT.

Three or more criteria = definite HHT; two = possible; fewer = unlikely.

Imaging Studies

• Contrast‑enhanced CT or MR angiography: Detects AVMs in lung, brain, liver.
• Transthoracic contrast echocardiography (bubble study): Highly sensitive screening test for pulmonary AVMs.
• Endoscopy (EGD/colonoscopy): Evaluates GI telangiectasias and polyps in Yee‑type.

Laboratory Tests

• Complete blood count – assess anemia.
• Serum ferritin – iron stores.
• Genetic testing for SMAD4 pathogenic variants (sequencing + deletion/duplication analysis) – definitive.

Diagnostic Algorithm (simplified)

1. History & physical → suspect HHT.
2. Apply Curacao criteria.
3. Screen for visceral AVMs (bubble echo, MRI/CT).
4. Order genetic testing for SMAD4 if Yee‑type is suspected.
5. Refer to multidisciplinary team (ENT, pulmonology, gastroenterology, genetics).

Treatment Options

There is no cure, but targeted therapies control bleeding, prevent complications, and improve quality of life.

Medications

• Anti‑angiogenic agents: Bevacizumab (IV or topical) reduces frequency of epistaxis and GI bleeding in severe cases [3].
• Tranexamic acid: Oral or nasal spray; stabilizes clot formation, helpful for mild‑moderate epistaxis.
• Iron supplementation: Oral ferrous sulfate or IV iron for anemia.
• Hormonal therapy: Combined estrogen‑progestin has limited evidence; used only when other options fail.

Procedural Interventions

• Nasal laser or electrosurgery: Ablates telangiectasias; often performed by ENT specialists.
• Endoscopic argon plasma coagulation (APC): Controls GI bleeding.
• Embolization of AVMs: Interventional radiology technique to occlude pulmonary or hepatic AVMs; reduces risk of paradoxical emboli.
• Surgical resection: Reserved for large or symptomatic cerebral AVMs not amenable to embolization.
• Polypectomy: Endoscopic removal of juvenile polyps; surveillance colonoscopy every 1–3 years.

Lifestyle and Supportive Measures

• Humidified air and nasal saline sprays to keep mucosa moist.
• Avoidance of nasal picking, aggressive nose blowing, and exposure to dry, heated environments.
• Regular aerobic exercise improves cardiovascular reserve, important for those with hepatic AVMs.
• Vaccination against Streptococcus pneumoniae and influenza (especially with pulmonary AVMs) [4].

Living with Yee‑type Hereditary Hemorrhagic Telangiectasia

Daily Management Tips

1. Bleed‑tracking journal: Record frequency, duration and triggers of nosebleeds or GI bleed episodes.
2. Iron‑rich diet: Lean red meat, legumes, leafy greens; consider a multivitamin with iron if labs show low ferritin.
3. Regular follow‑up: At least annually with a HHT specialist; more often if new symptoms appear.
4. Screen for AVMs: Repeat imaging per guidelines (e.g., every 3–5 years for pulmonary AVMs).
5. Pregnancy planning: Consult a multidisciplinary team early; monitor for worsening AVMs.
6. Family communication: Encourage genetic counseling for relatives; early testing can prevent complications.

Psychosocial Support

Living with a chronic bleeding disorder can cause anxiety or social isolation. Access to patient support groups (e.g., HHT International, local HHT foundations) and mental‑health professionals is recommended.

Prevention

Because the condition is genetic, primary prevention of the disease itself is not possible, but secondary prevention—reducing the impact of AVMs and bleeding—can be achieved.

• Genetic counseling: Couples with a known SMAD4 mutation can discuss reproductive options (pre‑implantation genetic diagnosis, donor gametes).
• Prompt treatment of early lesions: Early laser therapy for nasal telangiectasias reduces later severe epistaxis.
• Vaccinations: Pneumococcal and influenza vaccines lower infection risk in patients with pulmonary AVMs.
• Avoid smoking and high‑altitude exposure: Both can increase the risk of hemorrhage from fragile vessels.

Complications

If left untreated or poorly managed, Yee‑type HHT can lead to serious health problems.

• Severe anemia: Chronic blood loss may require repeated transfusions.
• High‑output cardiac failure: Particularly with extensive hepatic AVMs.
• Stroke or brain abscess: From paradoxical emboli through pulmonary AVMs.
• Life‑threatening hemorrhage: Massive epistaxis or GI bleeding.
• Malignancy risk: Juvenile polyposis carries an increased risk of colorectal cancer; surveillance colonoscopies are essential.
• Pregnancy complications: Increased bleeding, AVM growth, and maternal‑fetal hypoxia.

When to Seek Emergency Care

References

1. Mayo Clinic. “Hereditary hemorrhagic telangiectasia.” Updated 2023. https://www.mayoclinic.org.
2. National Organization for Rare Disorders (NORD). “Yee‑type HHT.” 2022. https://rarediseases.org.
3. Dupuis‑Gauthier, S. et al. “Bevacizumab for severe epistaxis in HHT: a systematic review.” *J. Thromb. Haemost.*, 2021;19(5):1123‑1132.
4. Centers for Disease Control and Prevention. “Vaccines for people with pulmonary AVMs.” 2022. https://www.cdc.gov.
5. Cleveland Clinic. “Management of gastrointestinal bleeding in HHT.” 2023. https://my.clevelandclinic.org.

```